Kalgutkar Amit S, Gardner Iain, Obach R Scott, Shaffer Christopher L, Callegari Ernesto, Henne Kirk R, Mutlib Abdul E, Dalvie Deepak K, Lee Jae S, Nakai Yasuhiro, O'Donnell John P, Boer Jason, Harriman Shawn P
Pharmacokinetics, Dynamics and Metabolism Department, PGRD, Groton, CT 06340, USA.
Curr Drug Metab. 2005 Jun;6(3):161-225. doi: 10.2174/1389200054021799.
The occurrence of idiosyncratic adverse drug reactions during late clinical trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal. Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiology of many drug-induced adverse reactions. Therefore, a thorough examination of the biochemical reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint. A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts. Potential strategies in the detection of reactive intermediates in biochemical systems are also discussed. The intention of this review is not to "black list" functional groups or to immediately discard compounds based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as experimental approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.
在临床试验后期或药物上市后发生的特异质性药物不良反应,可能会导致其使用受到严格限制,甚至被撤市。相对惰性的官能团代谢活化为具有反应活性的亲电中间体,被认为是许多药物引起的不良反应病因中的一个必然事件。因此,从安全性角度出发,对所有新候选药物中官能团/结构基序的生化反应性进行全面检查至关重要。本综述试图探讨的一个主要主题是,对药物设计中常用的官能团或结构基序的所有已知生物活化途径进行全面编目。还讨论了在生化系统中检测反应性中间体的潜在策略。本综述的目的不是将官能团“列入黑名单”,也不是基于化合物形成反应性代谢物的可能性而立即将其摒弃,而是作为一种资源,描述这些官能团的结构多样性以及可用于评估新候选药物中的“结构警示”是否会生物活化为反应性代谢物的实验方法。